Eisai

Eisai manufactures and distributes pharmaceutical products. Read more

494 Followers on Owler
494 Followers on Owler
494 Followers on Owler
494 Followers on Owler

Eisai

Eisai manufactures and distributes pharmaceutical products. Read more

Haruo Naito's photo - CEO of Eisai

CEO

Haruo Naito

CEO Approval Rating

82/100

Founded:

1941

Status:

PublicIndependent CompanyTokyo Stock Exchange4523

EISAI TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Drlindamd is seen as one of Eisai's top competitors. Drlindamd was founded in null, and is headquartered in South River, New Jersey. Drlindamd operates in the industry. Drlindamd generates $6.9B less revenue vs. Eisai.

Advaxis is a top competitor of Eisai. Advaxis was founded in 2002, and its headquarters is in Princeton, New Jersey. Advaxis competes in the Biotechnology industry. Advaxis has 10,981 fewer employees than Eisai.

Inovio is Eisai's #3 rival. Inovio was founded in Plymouth Meeting, Pennsylvania} in 1979. Like Eisai, Inovio also competes in the Pharmaceuticals field. Compared to Eisai, Inovio generates $6.9B less revenue.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Takeda a competitor of Eisai?

Eisai Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$6.9B

Eisai's revenue is the ranked lowest among it's top 10 competitors. The top 10 competitors average 25.8B. Over the last two quarters, Eisai's revenue has grown by 11.3%. Specifically, in Q3 2020's revenue was $1.7B; in Q2 2020, it was $1.5B.

Eisai Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Purdue Pharma L.P.

May 2019

Source »
undisclosed
Purdue Pharma develops and commercializes prescription medicines for healthcare professionals and caregivers.

-

Liaoning TianYi Biological Pharmaceutical Co., Ltd.

Dec 2015

Source »
$78.2M
-

-

AkaRx, Inc.

Jan 2010

Source »
$255M
-

-

MGI Pharma

Dec 2007

Source »
$3.9B
-

-

Onco-Related Products, Ligand Pharmaceuticals

Sep 2006

Source »
$205M
-

These are all the companies that Eisai has acquired. Eisai has acquired 5 companies and its latest acquisition was Purdue Pharma L.P. in May 2019. Purdue Pharma develops and commercializes prescription medicines for healthcare professionals and caregivers.

Eisai Funding History

No recent funding data found related to Eisai

Eisai Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

Oura is a Finland-based multisensor wellness ring developer that helps individuals to track and monitor their sleep and physical activities.
$100M
May 03, 2021
Series C
-
Neuroglee is a biotechnology company that develops and commercialize software to digital therapeutics for the treatment of neurodegenerative diseases.
$2.3M
Dec 01, 2020
Pre-Seed
-
Unlearn.AI develops a machine learning platform that allows drug developers to create digital twins.
$3M
Nov 04, 2020
Series A
-
Darmiyan develops a diagnostic platform that allows physicians to detect and monitor the effects of Alzheimer’s disease.
$6M
Apr 09, 2020
Seed
-
Numab is a biopharmaceutical company that develops and commercializes immuno-oncology therapies for the treatment of cancer.
$23.8M
Mar 08, 2020
Series B
-

These are all the companies that Eisai has invested in. Eisai has invested 5 companies and its latest investment was Purdue Pharma L.P. in May 2019. Purdue Pharma develops and commercializes prescription medicines for healthcare professionals and caregivers.

Eisai News

April 28, 2021FinanzNachrichten

RESONA and Eisai Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia in Saitama Prefecture, Japan

Building Dementia EcosystemTOKYO, Apr 28, 2021 - (JCN Newswire) - Saitama Resona Bank, Limited, a cor... See more »
April 27, 2021MarketScreener

and Eisai to Collaborate on Digital Therapeutics for Oncology Patients

(marketscreener.com) Collaboration and license agreement to develop digital therapeutics based on The... See more »
April 23, 2021FinanzNachrichten

Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Uterine Body Cancer in Japan

TOKYO, Apr 23, 2021 - (JCN Newswire) - Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc... See more »
April 23, 2021FinanzNachrichten

Gilead Sciences Submits New Drug Application in Japan for Filgotinib for the Treatment of Ulcerative Colitis with an Inadequate Response to Conventional Therapies

Application is Based on Phase 2b/3 SELECTION Study Data with Patients with Moderately to Severely Act... See more »
April 20, 2021The Pharma Letter

Encouraging Phase II data for Alzheimer's candidate BAN2401

Japanese drugmaker Eisai, one of an increasingly small number of major players still working in the A... See more »

Eisai Press Releases

February 4, 2021Cision Canada

Health Canada Authorizes DAYVIGO (lemborexant)

/CNW/ - Eisai Limited, the Canadian subsidiary of Eisai Inc., today announced the Canadian authorizat... See more »
December 8, 2020PR Newswire

#ThisIsMBC Perseverance Campaign from Eisai and METAvivor Captures the Joys, Difficulties and Realities Faced by People Living with Metastatic Breast Cancer

WOODCLIFF LAKE, N.J., Dec. 8, 2020 /PRNewswire/ -- Eisai Inc. and METAvivor today announced the launc... See more »
December 7, 2020PR Newswire

Eisai Presents Long-Term Seizure Freedom And Real-World Data Related To Anti-Epileptic Drug FYCOMPA At The AES 2020 Annual Meeting

WOODCLIFF LAKE, N.J., Dec. 7, 2020 /PRNewswire/ -- Eisai Inc. presented 52-week seizure freedom data ... See more »
December 1, 2020PR Newswire

Eisai To Present New Seizure Freedom And Real-World Clinical Practice Data Evaluating FYCOMPA Across Diverse Patient Types At Upcoming AES 2020 Annual Meeting

WOODCLIFF LAKE, N.J., Dec. 1, 2020 /PRNewswire/ -- Eisai Inc. announced today that new data on its an... See more »

Social Media

Eisai Headquarters

4-6-10 Koishikawa Bunkyo-ku

Tokyo, Tōkyō Prefecture112-8088

81-3-3817-3700

Driving Directions »

Trending Companies

Eisai Summary

ABOUT

Overview

Eisai manufactures and distributes pharmaceutical products. Eisai was founded in 1941. Eisai's headquarters is located in Tokyo, Tōkyō Prefecture, JP 112-8088. Eisai's CEO, Haruo Naito, currently has an approval rating of 82%. 83% of Owler community ...

CEO

Eisai's CEO, Haruo Naito, currently has an approval rating of 82%. Eisai's primary competitors are Drlindamd, Advaxis & Inovio.

Website

eisai.com

Frequently Asked Questions about Eisai

  1. When was Eisai founded?

    Eisai was founded in 1941
  2. Who is Eisai's CEO?

    Eisai's CEO is Haruo Naito
  3. How much revenue does Eisai generate?

    Eisai generates $6.9B in revenue
  4. How much funding does Eisai have?

    Eisai has historically raised $0 in funding
  5. Where is Eisai's headquarters?

    Eisai's headquarters is in Tokyo Tōkyō Prefecture, JP
  1. How many employees does Eisai have?

    Eisai has 10,998 employees
  2. What sector does Eisai operate in?

    Eisai is in Pharmaceuticals
  3. Who are Eisai's competitors?

    Eisai's top competitors are Drlindamd, Advaxis, Inovio
  4. Who has Eisai invested in?

    Eisai's has invested in companies such as Oura, Neuroglee Therapeutics, Unlearn.AI